Interrogation of Neurological Pathologies Associated with Mutations in Kif1a
Project Number5R61NS133266-02
Contact PI/Project LeaderLUTZ, CATHLEEN M
Awardee OrganizationJACKSON LABORATORY
Description
Abstract Text
PROJECT SUMMARY
KAND (KIF1A-associated neurological disorder) is caused by mutations in the KIF1A gene - a microtubule-
dependent motor protein that is responsible to transport cellular cargos in neurons. The majority of mutations
are dominant missense mutations that cluster in the conserved motor domain of the protein and lead to a
spectrum of neurological phenotypes beginning in childhood, including muscle weakness, microcephaly,
peripheral neuropathy, intellectual disability, autism, optic nerve and cerebellar atrophy. Without treatment,
children and adults affected by KAND suffer from the progressive loss of their mobility, vision and even early
death due to intractable epilepsy and complications of respiratory illness. Mouse models are a critical component
to both understanding disease mechanisms and to serve as a key platform for preclinical testing of novel
therapeutics. Unfortunately, mouse models to advance our understanding of KAND biology and therapeutics are
severely lacking, although very much in reach.
This proposal aims to build on our current knowledge of KAND to design mouse models that will not only provide
patient avatars for KAND disease pathophysiology but will also serve to address important questions around the
timing of therapeutic rescue, effects of overexpression, what cell types are required for effective treatment and
how much genetic correction is required for disease modulation. Importantly, the models will be valuable for pre-
clinical testing of therapeutics. The work described in this proposal leverages recently published Natural History
Studies by our clinical collaborator, Dr. WendyChung, which provides ongoing insight into the clinical features,
prevalence and biomarkers associated with this patient community. Our overall goals are to provide the scientific
community with well designed, rigorously tested mouse models that recapitulate key aspects of KAND disease
manifestations to be used, without restriction, throughout academia and industry for research and therapeutic
discovery.
Public Health Relevance Statement
PROJECT NARRATIVE
KAND (KIF1A-associated neurological disorder) is a devastating disease diagnosed in childhood and caused by
mutations in the KIF1A gene - a microtubule-dependent motor protein that is responsible for axonal transport.
Without treatment, children and adults affected by KAND suffer from the progressive loss of their mobility, vision
and even early death due to intractable epilepsy and complications of respiratory illness. This proposal aims to
generate much needed mouse models that will serve as patient avatars for advancing our understanding of
pathophysiology and therapeutic testing.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
042140483
UEI
XR6LMXNKDJJ1
Project Start Date
01-September-2023
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$205,021
Direct Costs
$139,667
Indirect Costs
$65,354
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$205,021
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R61NS133266-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R61NS133266-02
Patents
No Patents information available for 5R61NS133266-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R61NS133266-02
Clinical Studies
No Clinical Studies information available for 5R61NS133266-02
News and More
Related News Releases
No news release information available for 5R61NS133266-02
History
No Historical information available for 5R61NS133266-02
Similar Projects
No Similar Projects information available for 5R61NS133266-02